Short Interest in China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Declines By 99.0%

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) was the target of a large decline in short interest during the month of February. As of February 13th, there was short interest totaling 74,183 shares, a decline of 99.0% from the January 29th total of 7,347,822 shares. Approximately 8.0% of the shares of the company are sold short. Based on an average daily volume of 1,094,984 shares, the days-to-cover ratio is presently 0.1 days. Based on an average daily volume of 1,094,984 shares, the days-to-cover ratio is presently 0.1 days. Approximately 8.0% of the shares of the company are sold short.

Wall Street Analyst Weigh In

Separately, Wall Street Zen raised China SXT Pharmaceuticals to a “sell” rating in a report on Saturday, February 7th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has a consensus rating of “Sell”.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Virtu Financial LLC grew its stake in China SXT Pharmaceuticals by 107.5% in the 3rd quarter. Virtu Financial LLC now owns 28,983 shares of the company’s stock valued at $46,000 after acquiring an additional 15,013 shares during the period. XTX Topco Ltd acquired a new position in China SXT Pharmaceuticals during the fourth quarter worth $36,000. Finally, Citadel Advisors LLC purchased a new position in China SXT Pharmaceuticals during the third quarter valued at $78,000. 5.02% of the stock is owned by institutional investors and hedge funds.

China SXT Pharmaceuticals Stock Up 7.6%

SXTC opened at $2.42 on Friday. The company has a fifty day moving average of $76.83 and a two-hundred day moving average of $174.67. China SXT Pharmaceuticals has a fifty-two week low of $1.96 and a fifty-two week high of $1,046.98.

China SXT Pharmaceuticals (NASDAQ:SXTC) last posted its earnings results on Wednesday, December 31st. The company reported ($4.50) EPS for the quarter. The firm had revenue of $0.31 million during the quarter.

China SXT Pharmaceuticals Company Profile

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.